Ireland
--:--IST
Priya Life Science Compound trial record
Compound · clinical trials

Belatacept clinical trials

Also listed in trial records as Nulojix, Simulect
Source: ClinicalTrials.gov, U.S. National Library of Medicine — the 7 trials in our France, Italy, UK, USA, Germany, Spain, Netherlands, Belgium, Norway and Canada registers that name Belatacept as an intervention. Synced 13 Nov 2026
7Current trials
4Recruiting now
6Lead sponsors
10Country registers
At a glance

Belatacept is named as an intervention in 7 current clinical trials in our France, Italy, UK, USA, Germany, Spain, Netherlands, Belgium, Norway and Canada registers. 4 are recruiting patients now. The most common phase is Observational. The sponsor with the most trials is University Hospital, Rouen (2). The most-studied condition is Renal Allograft Recipients. The EU clinical trials register (CTIS) separately lists 1 authorised or ongoing trial.

Where Belatacept is approved

All regulators →

Of the three regulators tracked here, the first to approve Belatacept was the US, on 15 Jun 2011. It is approved in 2 of the 3 regulators tracked here.

USUnited States (FDA)
15 Jun 2011
Nulojix
BLA125288 on Drugs@FDA
First original NDA/BLA approval
EUEuropean Union (EMA)
17 Jun 2011
Nulojix
EMA product page
First centralised authorisation
CACanada (Health Canada)
No new-drug Notice of Compliance since 1994
First new-drug NOC

From the regulators' own registers: FDA Drugs@FDA, the EMA medicines list and Health Canada's Notice of Compliance database. Dates are the first listed approval of a product containing only this substance; combination products and nationally authorised EU medicines are not counted.

What health systems spend on Belatacept

All medicines →
ENNHS England
Not dispensed in the community in England in the last 12 months under this name
Net ingredient cost, community prescriptions
USUS Medicaid
$8.3m
10,909 prescriptions in 2025 · Nulojix
-4% on 2024
Amount Medicaid reimbursed, before rebates

From NHSBSA Prescription Cost Analysis (Open Government Licence v3.0) and CMS State Drug Utilization Data. Both are gross amounts: neither system publishes its discounts or rebates per drug. Products combining several substances are not counted here.

How Belatacept works

All drug targets →
  • T-lymphocyte activation antigen CD86 inhibitor Inhibitor
    Target: CD86 CD86 molecule
    ✓ In ChEMBL and the Guide to Pharmacology
  • T-lymphocyte activation antigen CD80 inhibitor Inhibitor
    Target: CD80 CD80 molecule
    ✓ In ChEMBL and the Guide to Pharmacology
Other medicines acting on CD86
Other medicines acting on CD80
Diseases it has been tested for in clinical trials, by furthest phase
  • Chronic kidney diseasePhase 3
  • HyperglycemiaPhase 2
  • HypoglycemiaPhase 2
  • ProteinuriaPhase 2
  • Chronic lung allograft dysfunctionPhase 2
  • Lung transplantationPhase 2
  • Type 1 diabetes mellitusPhase 2
  • Rheumatoid arthritisPhase 1/2
  • Stage 5 chronic kidney diseasePhase 1/2

Mechanisms and diseases from ChEMBL via the Open Targets Platform (release 26.09), ChEMBL record CHEMBL1742990, CC BY-SA 3.0. Targets checked against the IUPHAR/BPS Guide to PHARMACOLOGY (2026.3.1), ligand 6892, CC BY-SA 4.0. Trial phases are not approvals: approved uses are shown from the regulators' own records where we hold them.

NICE appraisals of Belatacept

All NICE appraisals →

NICE, which decides whether the NHS in England should fund new medicines, has published 2 technology appraisals of Belatacept. 2 are current, and 2 of these recommend it for at least some patients.

AppraisalNICE recommendationPublishedStatus
Immunosuppressive therapy for kidney transplant in adults
NICE TA481
Recommended Not recommended11 Oct 2017Current
Immunosuppressive therapy for kidney transplant in children and young people
NICE TA482
Recommended Not recommended11 Oct 2017Current

NICE decisions apply to the NHS in England. In Ireland the HSE decides on reimbursement, advised by the National Centre for Pharmacoeconomics. Titles, categories and dates link to the guidance on nice.org.uk. © NICE 2026 technology appraisal guidance. Available from www.nice.org.uk/guidance. All rights reserved. Subject to Notice of rights. NICE guidance is prepared for the National Health Service in England. All NICE guidance is subject to regular review and may be updated or withdrawn. NICE accepts no responsibility for the use of its content in this product/publication.

Patient leaflets for Belatacept

The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.

  • IE
    Ireland: 1 product on the HPRA list
    Each product record links to the HPRA, which publishes the leaflet and SmPC.
  • EU
    European Union: Nulojix
    EMA product information: package leaflet and summary of product characteristics in every EU language.
  • UK
    United Kingdom: Search MHRA Products
    Patient information leaflets and SmPCs for UK-licensed products.
  • US
    United States: Search DailyMed
    FDA-approved labels, including patient and medication guides.

Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.

Reference identifiers for Belatacept

ATC code
L04AA28
ChEMBL
CHEMBL1742990
DrugBank
DB06681
CAS number
706808-37-9
FDA UNII
E3B2GI648A
Wikidata
Q4881990
Wikipedia
Belatacept

Codes that identify this medicine in other databases, from Wikidata (CC0), matched by its ChEMBL ID. The ATC code is the WHO classification of what the medicine is used for.

Trials by status

  • Recruiting457%
  • Active, closed343%

Trials by phase

  • Observational343%
  • Phase 2229%
  • Phase 3114%
  • Phase 4114%
01

Clinical trials of Belatacept

7 trials
StudyPhaseStatusLead sponsorRegisters
Comparison of the Effects of Belatacept and Anticalcineurins on Endothelial Function in Renal Transplant Patients - <BELAFENDO>
NCT06291077 · ClinicalTrials.gov ↗ · Kidney Diseases
Phase 4 Recruiting University Hospital, Rouen France
A Study to Evaluate the Benefits and Risks of Conversion of Existing Adolescent Kidney Transplant Recipients Aged 12 to <18 Years to a Belatacept-based Immunosuppressive Regimen as Compared to Continuation of a Calcineurin Inhibitor-based Regimen, and Their Adherence to Immunosuppressive Medications
NCT04877288 · Renal Allograft Recipients
Phase 3 Recruiting Bristol-Myers Squibb UK, USA, Germany, France, Spain, Italy, Netherlands, Belgium, Norway
Pilot Study: Interest of Belatacept as a Non-nephrotoxic Immunosuppressive Treatment in Cardiac Transplant Patients at Risk of Chronic Renal Failure (BELACOEUR)
NCT04180085 · ClinicalTrials.gov ↗ · Heart Transplant Failure
Phase 2 Recruiting Nantes University Hospital France
Advancing Transplantation Outcomes in Children
NCT06055608 · ClinicalTrials.gov ↗ · Kidney Transplant
Phase 2 Recruiting National Institute of Allergy and Infectious Diseases (NIAID) Canada
Impact of the Microbiota on the Likelihood of Renal Graft Rejection
NCT04736381 · ClinicalTrials.gov ↗ · Kidney Transplant Rejection
Observational Active, closed Institut National de la Santé Et de la Recherche Médicale, France France
Evolution of CMV Antiviral T-cell Immunity Over the Next Six Months Initiation of Treatment With Belatacept.
NCT05708534 · ClinicalTrials.gov ↗ · Kidney Transplant Infection
Observational Active, closed University Hospital, Rouen France
1 vs 7 RATG Infusions in Renal Transplantation
NCT06374095 · ClinicalTrials.gov ↗ · Kidney Replacement
Observational Active, closed Mario Negri Institute for Pharmacological Research Italy

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.

02

Belatacept in the EU trials register (CTIS)

1 trial

Authorised or ongoing trials in the EU Clinical Trials Information System that list a product containing Belatacept. Many trials are registered in both CTIS and ClinicalTrials.gov, so these are shown separately rather than added to the count above. Trials with a site in Ireland are listed first.

StudyPhaseStatusSponsorCountries
SISTAR: Stratifying Immunosuppression to Allogenic Risk. A randomized, open label, assessor blinded, controlled, non-inferiority, safety study of half- vs standard dose immunosuppression in kidney transplant recipients with a well-matched donor.
2025-525091-29-00 · CTIS ↗ · Surgical Procedures, Operative
Phase 2 Ongoing Medical University Of Vienna Austria
03

Belatacept across our data

Ireland · EU · US

The same active substance in our other registers, matched by its exact name. Each entry links to the register record it comes from.

Licensed in Ireland (HPRA)

1 single-substance product containing Belatacept on the HPRA medicines list.

All 1 Irish product →

Supply shortages

  • NulojixEU (EMA) · Shortage resolved · first published 17 Mar 2017
04

Conditions studied with Belatacept

7 conditions
Renal Allograft Recipients1Heart Transplant Failure1Kidney Transplant Rejection1Kidney Diseases1Kidney Transplant Infection1Kidney Transplant1Kidney Replacement1
07

Related compounds

08

Questions about Belatacept trials

How many clinical trials are testing Belatacept?

7 current trials in our France, Italy, UK, USA, Germany, Spain, Netherlands, Belgium, Norway and Canada registers name Belatacept as a drug or biological intervention, as of the registry sync on 13 November 2026. Completed and withdrawn studies are not counted.

Are Belatacept trials recruiting patients?

Yes. 4 of the 7 trials are recruiting: 3 with sites in France, 1 with sites in Italy, 1 with sites in UK, 1 with sites in USA, 1 with sites in Germany, 1 with sites in Spain, 1 with sites in Netherlands, 1 with sites in Belgium, 1 with sites in Norway and 1 with sites in Canada. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Who sponsors Belatacept clinical trials?

University Hospital, Rouen (2), Bristol-Myers Squibb (1), Nantes University Hospital (1) and Institut National de la Santé Et de la Recherche Médicale, France (1), among 6 lead sponsors in total. The number in brackets is how many trials each organisation leads.

Is Belatacept licensed in Ireland?

Yes. The HPRA medicines list includes 1 single-substance product containing Belatacept, for example NULOJIX 250 mg powder for concentrate for solution for infusion (Bristol-Myers Squibb Pharma EEIG). A licence does not mean a product is currently marketed or reimbursed; see each product's record.

Is there a Belatacept shortage?

The registers we track list 1 entry for Belatacept: Nulojix (EU: shortage resolved). Shortages are product- and country-specific; check with a pharmacist.

Where does this information come from?

Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Belatacept works or whether it is effective, and it is not medical advice.

Approvals, shortages and trials, every Friday

One email a week with new EMA and FDA approvals, EU and US medicine shortages, how many trials are recruiting in Ireland, and the week's Irish pharma news.

Free. Unsubscribe from any email with one click. See our privacy policy.

How this page is built

Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Belatacept works or whether it is effective. Each trial links to its own record so you can check it yourself.

This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Belatacept (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 13 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.